Microbio Co., Ltd. 4128.TWO Stock
Microbio Co., Ltd. Price Chart
Microbio Co., Ltd. 4128.TWO Financial and Trading Overview
| Microbio Co., Ltd. stock price | 43.85 TWD |
| Previous Close | 55.89 TWD |
| Open | 57.2 TWD |
| Bid | 57.5 TWD x 0 |
| Ask | 57.7 TWD x 0 |
| Day's Range | 56.9 - 58.4 TWD |
| 52 Week Range | 42.29 - 74.04 TWD |
| Volume | 3.98M TWD |
| Avg. Volume | 2.93M TWD |
| Market Cap | 29.39B TWD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.11 TWD |
| Forward Dividend & Yield | 0.04 (0.069%) |
| Ex-Dividend Date | June 16, 2023 |
| 1y Target Est | N/A |
4128.TWO Valuation Measures
| Enterprise Value | 29.57B TWD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 17.21196 |
| Price/Book (mrq) | 2.3954341 |
| Enterprise Value/Revenue | 17.32 |
| Enterprise Value/EBITDA | -165.875 |
Trading Information
Microbio Co., Ltd. Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 10.13% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 74.04 TWD |
| 52 Week Low | 42.29 TWD |
| 50-Day Moving Average | 56.38 TWD |
| 200-Day Moving Average | 58.04 TWD |
4128.TWO Share Statistics
| Avg. Volume (3 month) | 2.93M TWD |
| Avg. Daily Volume (10-Days) | 2.2M TWD |
| Shares Outstanding | 511.1M |
| Float | 384.37M |
| Short Ratio | N/A |
| % Held by Insiders | 31.89% |
| % Held by Institutions | 10.83% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.04 |
| Trailing Annual Dividend Yield | 0.071% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1098108:1000000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -41.11% |
| Operating Margin (ttm) | -16.17% |
| Gross Margin | 40.08% |
| EBITDA Margin | -10.44% |
Management Effectiveness
| Return on Assets (ttm) | -1.12% |
| Return on Equity (ttm) | -5.17% |
Income Statement
| Revenue (ttm) | 1.71B TWD |
| Revenue Per Share (ttm) | 3.35 TWD |
| Quarterly Revenue Growth (yoy) | -3.59% |
| Gross Profit (ttm) | 691.3M TWD |
| EBITDA | -178284992 TWD |
| Net Income Avi to Common (ttm) | -702006016 TWD |
| Diluted EPS (ttm) | -1.38 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.8B TWD |
| Total Cash Per Share (mrq) | 7.53 TWD |
| Total Debt (mrq) | 501.86M TWD |
| Total Debt/Equity (mrq) | 3.58 TWD |
| Current Ratio (mrq) | 10.486 |
| Book Value Per Share (mrq) | 24.004 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 184.52M TWD |
| Levered Free Cash Flow (ttm) | 140.56M TWD |
Profile of Microbio Co., Ltd.
| Country | Taiwan |
| State | N/A |
| City | Taipei |
| Address | No. 3, Park St. |
| ZIP | 115 |
| Phone | 886 2 2655 8558 |
| Website | https://www.microbio.com.tw |
| Industry | Packaged Foods |
| Sector(s) | Consumer Defensive |
| Full Time Employees | N/A |
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.
Q&A For Microbio Co., Ltd. Stock
What is a current 4128.TWO stock price?
Microbio Co., Ltd. 4128.TWO stock price today per share is 43.85 TWD.
How to purchase Microbio Co., Ltd. stock?
You can buy 4128.TWO shares on the Taipei Exchange exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Microbio Co., Ltd.?
The stock symbol or ticker of Microbio Co., Ltd. is 4128.TWO.
Which industry does the Microbio Co., Ltd. company belong to?
The Microbio Co., Ltd. industry is Packaged Foods.
How many shares does Microbio Co., Ltd. have in circulation?
The max supply of Microbio Co., Ltd. shares is 560.16M.
What is Microbio Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Microbio Co., Ltd. PE Ratio is now.
What was Microbio Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Microbio Co., Ltd. EPS is -2.11 TWD over the trailing 12 months.
Which sector does the Microbio Co., Ltd. company belong to?
The Microbio Co., Ltd. sector is Consumer Defensive.